Media coverage about Nabriva Therapeutics AG (NASDAQ:NBRV) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nabriva Therapeutics AG earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.1414451441128 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
- Seattle Genetics (SGEN) & Nabriva Therapeutics AG (NBRV) Critical Review (americanbankingnews.com)
- 10% Owner of Nabriva Therapeutics plc – Ordi (NASDAQ:NBRV), Hbm Healthcare Investments (Ca, sells 10,458 shares worth $90,236 (empowerednews.net)
- Nabriva Therapeutics Becomes Oversold (NBRV) (thestreet.com)
- Nabriva Therapeutics AG (NBRV) Major Shareholder Sells $313,364.48 in Stock (americanbankingnews.com)
- $1.32 Million in Sales Expected for Nabriva Therapeutics plc – (NBRV) This Quarter (americanbankingnews.com)
Shares of Nabriva Therapeutics AG (NBRV) traded down 19.10% during mid-day trading on Friday, reaching $6.86. The company’s stock had a trading volume of 208,793 shares. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $12.75. The firm’s market cap is $184.11 million. The firm’s 50-day moving average price is $9.09 and its 200 day moving average price is $10.25.
Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping the Zacks’ consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $1.34 million. On average, analysts expect that Nabriva Therapeutics AG will post ($2.28) EPS for the current year.
NBRV has been the topic of a number of recent research reports. Cantor Fitzgerald initiated coverage on Nabriva Therapeutics AG in a report on Thursday, June 22nd. They issued a “buy” rating and a $16.00 target price on the stock. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Saturday, May 27th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. SunTrust Banks, Inc. initiated coverage on Nabriva Therapeutics AG in a report on Friday, August 25th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, ValuEngine raised Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Nabriva Therapeutics AG has a consensus rating of “Buy” and a consensus price target of $16.25.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Nabriva Therapeutics AG (NBRV) Stock Price” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/09/17/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-nabriva-therapeutics-ag-nbrv-stock-price.html.
In other news, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $10.94, for a total value of $143,609.38. Following the completion of the transaction, the insider now owns 2,583,229 shares of the company’s stock, valued at approximately $28,260,525.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 279,170 shares of company stock valued at $2,886,709. Insiders own 2.75% of the company’s stock.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.